-
Therapeutic Drug Evaluation
We are significantly active in the evaluation of therapeutic drugs for many areas of study such as oncology, pulmonology, and neurology. Our oncology studies evaluate therapeutic drugs for major disease sites such as Breast, Lung, Colon, and many other cancer diagnoses. Our pulmonology studies evaluate therapeutic drugs for Pulmonary Hypertension, Pulmonary Arterial Hypertension, Interstitial Lung Disease, and Pulmonary Fibrosis. Our neurology studies focus on the evaluation of therapeutic drug treatments for Alzheimer’s Disease.
-
Medical Oncology Clinical Study Management
We specialize in managing medical oncology clinical trials from start to finish. As members of ECOG, CTSU, RTOG/NRG Oncology, we manage the complete spectrum of clinical trials from cooperative groups to pharmaceutical sponsors to investigator directed clinical trials. These clinical trials vary in range from observational/registry to Phase II-Phase IV trials.
-
Pharmacogenomics
Medical diagnostics and therapeutics will experience a significant shift over the next 2-10 years as the old “one treatment fits all” model is replaced with a more personalized treatment and disease tracking system based on genomic make-up. Patients will be grouped into subsets based on the presence or absence of specific gene mutations for each disease. Today, a growing number of interest and research is therefore de-coding the relevance of DNA profiles. We currently participate in biobank blood draw trials that can significantly expand to cover a wide breadth of diagnoses. .
-
Radiotracer Development
We assist in the development of new radiolabeled tracers and biomarkers for use in companion diagnostics, assessing pharmacological effects, molecular drug delivery efficiencies and drug retention/uptake studies.
-
Physician Clinical Research Training
As clinical research regulations continue to grow more complex, it is critically important that principal investigators are up to date on all regulations and good clinical practices. We inform and educate principal investigators on all timely aspects of new clinical research regulations and good clinical practices.
